Wearable Injectors and Connected Devices Conference 2020

SMi Group 7 - 8 October 2020, London, United Kingdom.
The global wearable devices market size is expected to reach a value of $62.82 billion USD by 2025 with time dependent delivery, improved patient experience and adherence and large volume administration with minimal injection pain and being key factors driving the market.

With that in mind, SMi is proud to present Europe's only Wearable Injectors Conference, taking place on the 7th-8th of October 2020, in London.

SMi's 2nd annual Wearable Injectors and Connected Devices conference will explore the latest digital applications for on-body devices through industry case studies and perspectives, advances in device design for large volume delivery, drug/device compatibility for wearable injectors and real world examples from industry thought leaders on a patient-centric approach. Furthermore, the key regulatory considerations and guidance of the field will be presented by regulatory, notified body and industry experts for a comprehensive outlook of this exciting and ever-growing field.

This two-day agenda offers you peer-to-peer networking with Global Device Development Managers, Senior Connectivity Engineers, Leaders in Device Data Generation, Human Factors Directors and many more.

Benefits of Attending

  • EXPLORE the growing potential of connectivity and digital health to improve patient experience and treatment
  • UNDERSTAND the key regulatory considerations in industry with representation from regulatory and notified bodies
  • ASSESS advances in device design and development for large volume delivery via on-body injectors
  • GAIN insights into drug/device compatibility and packaging for wearable injectors

Early-Bird Rates

  • Book by June 30th to save £300
  • Book by August 31st to save £200

For further information and to register, please visit:
http://www.wearable-injectors.co.uk/wpnwl

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...